Cidara Therapeutics’ Post

Paper where I share first authorship just got out! We show exceptional efficacy of drugs combo - pegylated interferon-alpha and 5-azacytidine - in combating myeloproliferative diseases in preclinical studies. Followup clinical study is planned 🤞.

🆕 A new way to evaluate hepatic function in vitro. EpiLiver is a physiologically-relevant in vitro hepatic tissue that models the complexity, function, and structure of the human liver. It provides valuable insight into human responses to pharmacological drug candidates, the study of hepatotoxicity and its mechanisms, and reduces animal usage in preclinical drug screening.   The first of its kind lab-grown human liver tissue is currently available as a beta product from MatTek. Learn more about EpiLiver: https://bit.ly/3TMLsoo #betterscience #livermodel #invitrotechnology

Targeting two tumor-associated antigens with a bsADC is a therapeutic strategy to reduce off-tumor toxicity and improve antitumor efficacy. Our off-the-shelf bsADCs are generated with fully human antibodies,  and many include a novel linker/payload system. With preclinical data disclosed at SITC/AACR meetings, we offer 20+ advanced bsADC assets for collaboration. Ready to enhance your pipeline? Contact us for data packages and licensing opportunities: bd-licensing@biocytogen.com #bispecific #ADC #fullyhumanantibody #antitumor #monoclonal #antibodydiscovery #AntibodyTherapeutics #drugdiscovery #antibodylicense #drugdevelopment

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal... READ ARTICLE FOLLOW #ProducedbyANP 🎬 #ANPharmaUpdate #Pharmanews #pharmamarketing #pharmamarketingnews

The only missiles I agree with. ADCs! - Antibody drug conjugates (ADCs) are an innovative approach for targeted cancer therapy, using the specificity of monoclonal antibodies together with the potency of cytotoxic drugs (APIs or HPAPIs). ADCs function as precision-guided missiles, targeting cancer cells while sparing the healthy ones, minimizing adverse effects commonly associated with traditional chemotherapy. ADCs harness the power of monoclonal antibodies to selectively bind to specific proteins expressed on cancer cells, delivering potent cytotoxic payloads directly to the tumor. This targeted delivery mechanism not only enhances efficacy but reduces toxicity, making the treatment completely revolutionary. That's the pinnacle of precision medicine! Speakers in the podcast: - Lonza’s senior director of Commercial Development of BioConjugates, Iwan Bertholjotti - Laurence Bonnafoux, Lonza’s Head of MSAT BioConjugates Host: Lonza's Associate Director Science Communications - Martina Ribar Hestericová PhD https://lnkd.in/eZu3-wBJ #antibodydrugconjugates #adcs #biotech #biotechnology #biopharma #biopharmaceuticals

Evaluate antibody-drug conjugate (ADC) candidate with Discovery’s Gentest® ADC Off-Target Toxicity and ADC Linker Stability Assay Services. Unlike animal studies, these assays generate biologically relevant data faster, accelerating IND submission whenever hematotoxicity is a concern.    Learn more:  https://lnkd.in/eBS5pKhM   We use modified colony-forming cell (CFC) assays to detect neutropenia and thrombocytopenia potential and assess ADC linker stability in the presence of neutrophils, which are known to release enzymes capable of cleaving linkers and releasing ADC payloads.  Speak with our expert today.    #ADC #hematotoxicity #neutropenia #thrombocytopenia   

Preclinical efficacy and pharmacokinetics of anRNA-encoded T cell–engaging bispecific antibodytargeting human claudin 6 https://lnkd.in/gRd6Tk8u

Meet our latest post in the Biologics campaign! Today, we will focus on the Spleen tyrosine kinase (Syk), a promising therapeutic target for treating numerous immune diseases. ✅Discover a set of Chemspace Biologics specially selected for studying Syk-related diseases: https://buff.ly/3xkY7aL Syk is a nonreceptor tyrosine kinase that plays an important role in the signaling pathways of the immune system. It is expressed in various types of immune cells, including macrophages and neutrophils. It involves biological processes such as adaptive immunity, host-virus interaction, angiogenesis, and alternative splicing. Chemspace provides a comprehensive solution for your research project including Biologics, Small Molecules, and Discovery Services. Contact us at info(AT)chem-space.com, and we will be happy to be a part of your scientific journey!💚 #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

Did you know that Transfer RNAs (tRNAs) are not just key players in protein translation, but can also give rise to a unique class of small non-coding RNAs with therapeutic potential? This is what we presented yesterday at the mRNA-Based Therapeutic Summit in Berlin! And look here: https://lnkd.in/dikbXkMB Recent research reveals their diverse roles in cancer, challenging the traditional view of tsRNAs as mere byproducts. Stay tuned for a closer look at how tsRNAs revolutionize our understanding of cancer and pave the way for innovative therapies. 🌐🔬 #CancerResearch #RNARevolution #InnovationInMedicine #RNA #TheRibosomeCompany

Check out the newly published paper "SHP2 Inhibition Displays Efficacy as a Monotherapy and in Combination with JAK2 Inhibition in Preclinical Models of Myeloproliferative Neoplasms" This research demonstrates promising results in the use of SHP2 inhibitors, both as a standalone treatment and in combination with JAK2 inhibition, in preclinical models of myeloproliferative neoplasms. 🧬💊 This marks a significant step forward in our understanding of potential therapeutic strategies for these challenging conditions. The publication is now available, and I encourage everyone interested in the field to explore the details here: DOI: 10.1002/ajh.27282